(SC1), Health, demographic change and well-being

Giornata Nazionale di Lancio dei Bandi 2018-20 in Horizon 2020

International Research Co-Operative Group Min Salute/ISS. Ufficio 5 –Internazionalizzazione e promozione infrastrutture ricerca

•

•

•

•

0

5

10

15

20

25

30

2011 2012 2013 2014 2015 2016 2017

JPIAMR Membership

Paesi inclusi recentemente:Egitto, India, Irlanda e Sud Africa

PhaseI

PhaseII

PhaseIII

Basic Science

Pre-clinical

JPIAMR

National Science Research Agencies

EC FP / ERC

BARDA

IMI / ND4BB

NIH / NIAID

Wellcome Trust

CARB-X

GARDR-P

EIB’s InnovFin

UK / China Global Innovation FundRecently LaunchedExisted Prior 2016

JPIAMR FUNDING 2014-2017 (52 projects)

Therapeutics29%

Diagnostics0%

Surveillance4%

Transmission49%

Environment9%

Interventions9%

RESEARCH PROJECTS PER PILLAR

Therapeutics27%

Diagnostics14%Surveillance

27%

Transmission14%

Environment9%

Interventions9%

NETWORKS/WORKING GROUPS PER PILLAR

€

€

La «Strategic Research Agenda» definisce le sei aree prioritarie dove è necessaria la ricerca in AMR.

Strategic Research Innovation Agenda: Aggiornamento scientificoin stretta collaborazione con un’allineamento e co-operazionedelle policies nazionali, delle risorse e della capacità di ricerca, sviluppo e Innovazione.

Workshops e Guidelines da sviluppare collaborazioni traAccademia e Industria; link con altri programmi e strutture di ricerca Europee ed Internazionali.

AMR Projects Database• Mappatura dei progetti di ricerca, delle linee di ricerca

attive, centri/strutture di ricerca ed infrastructure.• Sviluppare un’interfaccia con tutti i dati della mappatura.

Research Activities• Lancio di tre “Join Research Calls” nel 2018 con un budget

preliminare di circa 15 M€• Call 2019: indagine per valutare topic d’interesse per i

paesi membri in AMR (in corso). • Nuovo ERANET 2019/20 : “AMR Intervention Trials”

L'esercizio di mappatura raccoglie informazioni su :

AMR research infrastructure: La mappatura dell'infrastruttura di ricerca AMR esistente all'interno degli stati membri faciliterà la coordinazione tra database e biobanche, garantendo un’efficace scambio di informazioni e campioni .

AMR research project : Dati su progetti di ricerca sulla resistenza antimicrobica intrapresa nei 26 paesi membri, nell'ambito dei sei temi prioritari identificati nella SRA- JPIAMR.

AMR research centers/units: Dati su centri di ricerca che hanno contributi significativi alla ricerca AMR. Una rete dinamica di tali unità di ricerca AMR fornirà uno stretto contatto tra il JPIAMR e la comunità scientifica e contribuirà a creare nuove capacità di ricerca nell'area dell'AMR.

AMR industry alliances and development: Verranno condotte mappature delle industrie che operano nel settore AMR e le loro esigenze specifiche per migliorare la condivisione dei dati e la comunicazione tra mondo accademico e industria.

AMR research funding: Dati sui finanziamenti dei progetti dai diversi bandi JPIAMR, agenzie di finanziamento nazionali e fondazioni internazionali. Per monitorare gli investimenti in progetti che vanno dalla ricerca di base, applicata e clinica, inclusi studi clinici, epidemiologici, sanitari, veterinari alla ricerca ambientale .

No Research

AMR25%

AMR R78%

20 feedback (IRCCS + ISS)

0 2 4 6 8 10 12 14

Etiology of antimicrobial resistance

Typing of AMR strains

Set-up and validation of new diagnostic tools

  Reduction of the use of antibiotics in animals

  New antibiotics into veterinary medicine

Monitoring of the appropriate use of antimicrobials

Prevention and control in healthcare settings

Development of new antimicrobials

Clinical trials on investigational new drugs preregistration

Synergic activities MDR Gram positive bacteria oldand new drugs

IRCCS + ISS

Research Area

@jpionamr www.jpiamr.eu

In February of 2017 the WHO released their global priority pathogen list of

antibiotic resistant bacteria (including Mycobacterium) to guide research,

discovery, and development of new antibiotics.

The 6th joint call from JPIAMR is a direct response to the list supporting new

targets, compounds and tools against antibiotic resistance.

Deadline preproposals March 2018

Deadline full proposals June 2018

No. of participating countries 15

Publication of call January 2018

Budget Approx. 13 million Euro

Project duration max 3 years

”New targets, compounds and tools”

JPIAMR 6th Call Pre-announcement

Participating countries & eligibility:Consortia of eligible scientists from Belgium (FWO), Czech Republic, Egypt, Finland, France, Germany, Ireland,

Israel, Italy, Latvia, Norway, Poland, Spain(MINECO), Sweden and Switzerland may apply for funding in this call.* Consortia must include a minimum of three eligible partners from at least three different countries participating in the call, and a maximum of 6 projectpartners (or 7 if a partner from Czech Republic, Latvia or Poland is included).*List is provisional – additional countries may join. Final eligibility conditions will be published when call opens.

@jpionamr www.jpiamr.eu

”New targets, compounds and tools”Drug-resistant bacteria identified by the WHO as priority pathogens

JPIAMR 6th Call Pre-announcement

PATHOGENS INCLUDED IN CALLPRIORITY 1: CRITICALAcinetobacter baumannii, carbapenem-resistantPseudomonas aeruginosa, carbapenem-resistantEnterobacteriaceae (including Klebsiella pneumoniae,Escherichia coli, Enterobacter spp., Serratia spp., Proteusspp., and Providencia spp, Morganella spp.), carbapenem-resistant, 3rd generation cephalosporin-resistantPRIORITY 2: HIGHEnterococcus faecium, vancomycin-resistantStaphylococcus aureus, methicillin-resistant,vancomycin intermediate and resistantHelicobacter pylori, clarithromycin-resistantCampylobacter, fluoroquinolone-resistantSalmonella spp., fluoroquinolone-resistantNeisseria gonorrhoeae, 3rd generation cephalosporin-resistant,fluoroquinolone-resistantPRIORITY 3: MEDIUMStreptococcus pneumoniae, penicillin-non-susceptibleHaemophilus influenzae, ampicillin-resistantShigella spp., fluoroquinolone-resistantStudies involving multi- and extensively drug resistantMycobacterium tuberculosis, that is also included on theWHO priority pathogen list, are eligible in this call.

@jpionamr www.jpiamr.eu

”New targets, compounds and tools” TOPICS:

JPIAMR 6th Call Pre-announcement

NEW TARGETS/MECHANISMSStudies of new bacterial targets or mechanisms of resistance (examples include studies on novel enzymeor efflux pump inhibitors or others), including studies aimed at understanding and overcoming the mechanismscontrolling the generation of resistance.NEW THERAPIESStudies of new compounds (including new antibiotics and alternatives). Strategies to inhibit or reduce the acquisition of resistance, such as single molecular agents effective against multiple targets as well as therapeutics that enhanceimmune-mediated pathogen elimination, disrupt colonisation or biofilm development, and reduce virulence.Discovery of novel therapies to overcome known antimicrobial resistance mechanisms and/or to restoresusceptibility to conventional antibiotics.NEW STRATEGIES/TOOLS/ASSAYSThat improve, enhance, and/or facilitate the identification or validation of new effective compounds ortherapies. For optimisation of drug use, dosage and delivery of new drugs. Exploring bacterial genes, e.g. expression of latent gene clusters.

NOT WITHIN THE SCOPE OF THE CALLInvestigations addressing cross talk between the host and pathogen, as well as the relationship betweenmicrobes, environment and infection.Studies on bacteria not on the WHO Global priority list.Investigations on initial steps of the infection process.Investigations based on, or involving, clinical trials.Re-evaluation of existing anti-microbial compounds in the context of their combination with new, innovativetargets, compounds or tools.

@jpionamr www.jpiamr.eu

Image licence from Adobe Stock

Connecting researchers in all

areas of AMR research in a One Health approach

Building capacity and

strengthening capability

Facilitating access to scientific

information and infrastructures

Global reach: Bridging

geographic borders

Break practical barriers

Increasing the visibility of the

AMR issue

Drive the uptake of research into

policy

JPIAMR VIRTUAL RESEARCH INSTITUTE: Obiettivo: facilitare interazioni e potenziare la ricerca in AMR a livello globale.

VRI Vision: ridurre il carico di AMR attraverso un approccio One Health.

VRI Mission: